Nature Communications (Mar 2022)
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
- Ezra Y. Rosen,
- Helen H. Won,
- Youyun Zheng,
- Emiliano Cocco,
- Duygu Selcuklu,
- Yixiao Gong,
- Noah D. Friedman,
- Ino de Bruijn,
- Onur Sumer,
- Craig M. Bielski,
- Casey Savin,
- Caitlin Bourque,
- Christina Falcon,
- Nikeysha Clarke,
- Xiaohong Jing,
- Fanli Meng,
- Catherine Zimel,
- Sophie Shifman,
- Srusthi Kittane,
- Fan Wu,
- Marc Ladanyi,
- Kevin Ebata,
- Jennifer Kherani,
- Barbara J. Brandhuber,
- James Fagin,
- Eric J. Sherman,
- Natasha Rekhtman,
- Michael F. Berger,
- Maurizio Scaltriti,
- David M. Hyman,
- Barry S. Taylor,
- Alexander Drilon
Affiliations
- Ezra Y. Rosen
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Helen H. Won
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Youyun Zheng
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Emiliano Cocco
- Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Duygu Selcuklu
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Yixiao Gong
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Noah D. Friedman
- Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Ino de Bruijn
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Onur Sumer
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Craig M. Bielski
- Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Casey Savin
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Caitlin Bourque
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Christina Falcon
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Nikeysha Clarke
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Xiaohong Jing
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Fanli Meng
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Catherine Zimel
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Sophie Shifman
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Srusthi Kittane
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Fan Wu
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Marc Ladanyi
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Kevin Ebata
- Loxo Oncology at Lilly
- Jennifer Kherani
- Loxo Oncology at Lilly
- Barbara J. Brandhuber
- Loxo Oncology at Lilly
- James Fagin
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Eric J. Sherman
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Natasha Rekhtman
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Michael F. Berger
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Maurizio Scaltriti
- Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- David M. Hyman
- Loxo Oncology at Lilly
- Barry S. Taylor
- Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Alexander Drilon
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-022-28848-x
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 9
Abstract
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRETTO-001 lung and thyroid cancer patients treated at a single site.
